Cellivery Therapeutics Inc
KOSDAQ:268600
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cellivery Therapeutics Inc
Interest Income Expense
Cellivery Therapeutics Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Interest Income Expense
-₩4.7B
|
CAGR 3-Years
-53%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Interest Income Expense
₩48.6B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Interest Income Expense
₩959.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Interest Income Expense
₩11.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Interest Income Expense
₩860.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Interest Income Expense
₩28B
|
CAGR 3-Years
12%
|
CAGR 5-Years
71%
|
CAGR 10-Years
53%
|
|
Cellivery Therapeutics Inc
Glance View
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
See Also
What is Cellivery Therapeutics Inc's Interest Income Expense?
Interest Income Expense
-4.7B
KRW
Based on the financial report for Jun 30, 2024, Cellivery Therapeutics Inc's Interest Income Expense amounts to -4.7B KRW.
What is Cellivery Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
13%
Over the last year, the Interest Income Expense growth was -170%. The average annual Interest Income Expense growth rates for Cellivery Therapeutics Inc have been -53% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
